Drugs / MDN-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07391839 | Aug 2025 → Aug 2026 overdue | hepatocellular carcinoma | Suzhou Mednovo Yi Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDN-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07391839 ↗ |
| Known as | Yttrium-90 Microsphere Injection | “MDN-001 Injection(Yttrium-90 Microsphere Injection)” NCT07391839 ↗ |